進階搜尋


   電子論文尚未授權公開,紙本請查館藏目錄
(※如查詢不到或館藏狀況顯示「閉架不公開」,表示該本論文不在書庫,無法取用。)
系統識別號 U0026-1601202004431600
論文名稱(中文) 唾液中 CXCL1 可作為口腔黏膜下纖維化病人惡性轉變的生物標記
論文名稱(英文) CXCL1 as a saliva biomarker in OSF patients with malignant transformation
校院名稱 成功大學
系所名稱(中) 口腔醫學研究所
系所名稱(英) Institute of Oral Medicine
學年度 108
學期 1
出版年 109
研究生(中文) 黃怡嘉
研究生(英文) Yi-Chia Huang
學號 T46054010
學位類別 碩士
語文別 英文
論文頁數 33頁
口試委員 指導教授-陳玉玲
口試委員-洪澤民
口試委員-吳梨華
口試委員-黃振勳
中文關鍵字 口腔黏膜下纖維化  唾液生物標記物  CXCL1  MIF 
英文關鍵字 OSF  Saliva biomarker  CXCL1  MIF 
學科別分類
中文摘要 口腔黏膜下纖維化是口腔黏膜慢性且持續性纖維化的癌前病變,口腔黏膜長期處在區域癌化的環境,使得惡性轉變更難以預測。過往針對口腔癌的檢體和正常組織相比,發現有特定細胞激素表現量不同。在大型的全國口腔黏膜篩檢的分析中,高危險族群日後轉變成口腔癌的唾液中亦有特定蛋白質高度表現。因此我們假定唾液中存有的細胞激素可能扮演著促進惡性轉變的功能,另外癌前病變組織或是惡性細胞的自分泌或是旁分泌信號也可能促進癌化。
首先我們分析了來自成大醫院口腔外科部門的 12 個臨床檢體,其中 6 個是單純患有口腔黏膜下纖維化的患者(並沒有其他癌前病變),另外 6 個則是除了口腔黏膜下纖維化還併有口腔癌的患者,使用人類細胞激素晶片分析,結果呈現在有口腔癌的組別,其細胞激素 CXCL 1 以及 macrophage inhibitory factor (MIF)的表現量都有明顯增加。
接著使用柳營奇美醫院自2012-2017的臨床唾液檢體來驗證這兩種細胞激素,利用酵素免疫分析法(ELISA)定量 CXCL 1 和 MIF,在口腔癌組別和單純口腔黏膜下纖維化的組別相比,CXCL 1 和 MIF 表現量在口腔癌組別都有較高的趨勢。分析 CXCL 1 和 MIF 表現量與臨床危險因素的相關性,在口腔癌細胞分化部分,CXCL 1 的濃度在重度分化和輕度分化的組別有統計上的顯著差別,在重度分化的組別,具有較高濃度的 CXCL1。
非侵入性診斷與預後是癌症精準醫療的趨勢,透過唾液細胞激素的檢測未來或可發展為口腔癌前病變惡轉為口腔癌非侵入性診斷與預後的指標,將有助於口腔癌的預防與治療。
英文摘要 Oral submucous fibrosis is a chronic and progressive fibrosis lesion of the oral mucosa and is considered as a precancerous lesion. The oral mucosa has been in a field cancerization for a long time, making the malignant transformation more difficult to predict. In the past, specimens for oral cancer were found to show different
amounts of specific cytokines compared to normal tissues. In a large-scale national analysis of oral screening, specific proteins are also highly expressed in saliva from high-risk populations that later turn into oral cancer. Therefore, we hypothesized that cytokines in saliva may play a role in promoting malignant transformation. In addition, autocrine or paracrine signals from precancerous lesions or malignant cells may also promote carcinogenesis.
First, we analyzed 12 clinical specimens from the department of oral and maxillofacial surgery of Cheng Kung University Hospital, of which 6 were OSF patients , and the other 6 were patients with OSF combined with OSCC were analyzed by human cytokine array. The results showed that in the group , OSF combined with OSCC , the cytokine level of CXCL 1 and macrophage inhibitory factor (MIF) were significantly increased.
Then we used saliva samples collected from department of oral and maxillofacial surgery Chi Mei Hospital, Liouying campus from 2012-2017 to verify these two cytokines, and use ELISA to quantify CXCL 1 and MIF. Compared with the group,
the expression of CXCL 1 and MIF had a higher trend in the OSF combined with OSCC group. To analyze the correlation between the expression of CXCL 1 and MIF and clinical risk factors. The concentration of CXCL 1 has statistically significant difference in the poor differentiated group.
Non-invasive diagnosis and prognosis tools are the trend of precision medicine. The salivary cytokines may be developed into a detection tool that point out oral precancerous lesion become a cancerous lesion, which will help prevent and treat oral cancer.
論文目次 中文摘要..…………………………………………………………….…………………... II
Abstract….………………………………………………………………..………………III
致謝………………………………………………………………………………………...V
Contents………………………………...………………………………………………...VI
Introduction………………………………………………………………………………..1
Oral cancer ……………………………………………………….……………………..1
Oral submucous fibrosis .….……………………………………….…………………...1
Field of cancerization…………………………………………………..………………..3
Salivary biomarker…………………………………………………….………………..4
CXCL1………………………………………………………………….………………..5
Macrophage migration inhibitory factor (MIF) …………………….………………..6
Motivation………………………………………………………………………………….8
Materials and methods .…………………….……………………………………………..9
Sample collection …………………….……………….…………………………………9
Saliva collection …………………….…………………………………………………...9
Cytokine array…………………….…………………………………………………...10
Protein expression assay……..………….……………………………………………..11
Enzyme-Linked ImmnuoSorbent Assay, ELISA…………………………………….11
Statistical analysis…………………….………………………………………………..13
Results……………...…………………….………………………………………………..14
1. Selection of overexpressed cytokines in saliva from OSF-OSCC patients by
cytokine array analysis…………...……...……………………………………………14
2. Quantification of cytokines levels in salivary samples of OSF patients and OSF-
OSCC patients….……………………………………………………………………15
3. Analysis of correlation of CXCL1 and MIF………………………………………15
4. Retrospective analysis the correlation between clinicopathological
characteristic and cytokines level…………………………..…………………………15
Discussion ……………………………………………………………………..………… 17
Conclusion……………………………………………………………………………...…21
References……………………………………………………………….………………..22
Tables and figures…………………………………………………….…………………..26
Table 1. Clinicopathological characteristics of OSF patients and OSF-OSCC
patients……………………….…………………….…………….……………….……26
Table 2. Clinicopathological characteristics (risk factors) of OSF-OSCC patients.. 27
Figure 1. Human cytokine arrays showed the levels of CXCL1 and MIF are higher in saliva from OSF-OSCC patients than those from OSF patients……………...…29
Figure 2. Quantification of cytokine concentration in saliva………………………...30
Figure 3. The correlation between cytokine concentration and age & MMO in all
patients……………………………….…………………….…………………………..31
Figure 4. Comparison of the correlation between CXCL1 level and clinicopathologic
factors in OSF combined with OSCC patients………………… ..…………………32
Figure 5. Comparison of the correlation between MIF level and clinicopathologic
factors in OSF combined with OSCC patients………..………………………………33
參考文獻 1 Paymaster, J. C. Cancer of the buccal mucosa; a clinical study of 650 cases in Indian patients. Cancer 9, 431-435 (1956).
2 Murti, P. R. et al. Malignant transformation rate in oral submucous fibrosis over a 17-year period. Community dentistry and oral epidemiology 13, 340-341 (1985).
3 Pindborg, J. J. & Sirsat, S. M. Oral submucous fibrosis. Oral surgery, oral medicine, and oral pathology 22, 764-779 (1966).
4 Harvey, W., Scutt, A., Meghji, S. & Canniff, J. P. Stimulation of human buccal mucosa fibroblasts in vitro by betel-nut alkaloids. Archives of oral biology 31, 45-49 (1986).
5 Tilakaratne, W. M., Klinikowski, M. F., Saku, T., Peters, T. J. & Warnakulasuriya, S. Oral submucous fibrosis: review on aetiology and pathogenesis. Oral oncology 42, 561-568 (2006).
6 Haque, M. F., Meghji, S., Khitab, U. & Harris, M. Oral submucous fibrosis patients have altered levels of cytokine production. Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 29, 123-128 (2000).
7 Utsunomiya, H. et al. Extracellular matrix remodeling in oral submucous fibrosis: its stage-specific modes revealed by immunohistochemistry and in situ hybridization. Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 34, 498-507 (2005).
8 Wahi, P. N., Luthra, U. K. & Kapur, V. L. Submucous fibrosis of the oral cavity. Histomorphological studies. British journal of cancer 20, 676-687 (1966).
9 Khanna, J. N. & Andrade, N. N. Oral submucous fibrosis: a new concept in surgical management. Report of 100 cases. International journal of oral and maxillofacial surgery 24, 433-439 (1995).
10 Passi, D. et al. Oral submucous fibrosis: Newer proposed classification with critical updates in pathogenesis and management strategies. National journal of maxillofacial surgery 8, 89-94 (2017).
11 Slaughter, D. P., Southwick, H. W. & Smejkal, W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 6, 963-968 (1953).
12 van Oijen, M. G. & Slootweg, P. J. Oral field cancerization: carcinogen-induced independent events or micrometastatic deposits? Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research,
cosponsored by the American Society of Preventive Oncology 9, 249-256 (2000).
13 Mohan, M. & Jagannathan, N. Oral field cancerization: an update on current concepts. Oncology reviews 8, 244 (2014).
14 Kujan, O., Glenny, A. M., Duxbury, J., Thakker, N. & Sloan, P. Evaluation of screening strategies for improving oral cancer mortality: a Cochrane systematic review. Journal of dental education 69, 255-265 (2005).
15 Stuani, V. T., Rubira, C. M., Sant'Ana, A. C. & Santos, P. S. Salivary biomarkers as tools for oral squamous cell carcinoma diagnosis: A systematic review. Head & neck 39, 797-811 (2017).
16 Li, Y. et al. Salivary transcriptome diagnostics for oral cancer detection. Clinical cancer research : an official journal of the American Association for Cancer Research 10, 8442-8450 (2004).
17 Cabrero-de Las Heras, S. & Martinez-Balibrea, E. CXC family of chemokines as prognostic or predictive biomarkers and possible drug targets in colorectal cancer. World journal of gastroenterology 24, 4738-4749 (2018).
18 Bandapalli, O. R. et al. Down-regulation of CXCL1 inhibits tumor growth in colorectal liver metastasis. Cytokine 57, 46-53 (2012).
19 Richmond, A. et al. Molecular characterization and chromosomal mapping of melanoma growth stimulatory activity, a growth factor structurally related to betathromboglobulin. The EMBO journal 7, 2025-2033 (1988).
20 Bechara, C., Chai, H., Lin, P. H., Yao, Q. & Chen, C. Growth related oncogene-alpha (GRO-alpha): roles in atherosclerosis, angiogenesis and other inflammatory conditions. Medical science monitor : international medical journal of experimental and clinical research 13, Ra87-90 (2007).
21 Yuan, M. et al. Tumor-Derived CXCL1 Promotes Lung Cancer Growth via Recruitment of Tumor-Associated Neutrophils. Journal of immunology research 2016, 6530410 (2016).
22 Wen, Y. et al. GROalpha is highly expressed in adenocarcinoma of the colon and down-regulates fibulin-1. Clinical cancer research : an official journal of the American Association for Cancer Research 12, 5951-5959 (2006).
23 Bucala, R. & Donnelly, S. C. Macrophage migration inhibitory factor: a probable link between inflammation and cancer. Immunity 26, 281-285 (2007).
24 Bernhagen, J. et al. MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 365, 756-759 (1993).
25 Weiser, W. Y. et al. Molecular cloning of a cDNA encoding a human macrophage migration inhibitory factor. Proceedings of the National Academy of Sciences of the United States of America 86, 7522-7526 (1989).
26 Kindt, N., Lechien, J. R., Nonclercq, D., Laurent, G. & Saussez, S. Involvement of CD74 in head and neck squamous cell carcinomas. Journal of cancer research and clinical oncology 140, 937-947 (2014).
27 Zeng, J., Quan, J. & Xia, X. Transient transfection of macrophage migration inhibitory factor small interfering RNA disrupts the biological behavior of oral squamous carcinoma cells. Molecular medicine reports 13, 174-180 (2016).
28 Yao, K. et al. Macrophage migration inhibitory factor is a determinant of hypoxiainduced apoptosis in colon cancer cell lines. Clinical cancer research : an official journal of the American Association for Cancer Research 11, 7264-7272 (2005).
29 Leng, L. et al. MIF signal transduction initiated by binding to CD74. The Journal of experimental medicine 197, 1467-1476 (2003).
30 Borghese, F. & Clanchy, F. I. CD74: an emerging opportunity as a therapeutic target in cancer and autoimmune disease. Expert opinion on therapeutic targets 15, 237251 (2011).
31 Cludts, S. et al. Increased expression of macrophage migration inhibitory factor during progression to hypopharyngeal squamous cell carcinoma. Anticancer research 30, 3313-3319 (2010).
32 Kindt, N. et al. Expression of macrophage migration-inhibitory factor is correlated with progression in oral cavity carcinomas. Anticancer research 32, 4499-4505 (2012).
33 MB, D. E. S., Curioni, O. A., Kanda, J. L. & MB, D. E. C. Serum and salivary macrophage migration inhibitory factor in patients with oral squamous cell carcinoma. Oncology letters 8, 2267-2275 (2014).
34 Lan, H. Y. et al. The pathogenic role of macrophage migration inhibitory factor in immunologically induced kidney disease in the rat. The Journal of experimental medicine 185, 1455-1465 (1997).
35 Gleber-Netto, F. O. et al. Salivary Biomarkers for Detection of Oral Squamous Cell Carcinoma in a Taiwanese Population. Clinical cancer research : an official journal of the American Association for Cancer Research 22, 3340-3347 (2016).
36 Lee, L. T. et al. Evaluation of saliva and plasma cytokine biomarkers in patients with oral squamous cell carcinoma. International journal of oral and maxillofacial surgery 47, 699-707 (2018).
37 Ye, M. Y. et al. Growth-regulated oncogene-alpha from oral submucous fibrosis fibroblasts promotes malignant transformation of oral precancerous cells. Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 47, 880-886 (2018). 38 Kodet, O. et al. Melanoma cells influence the differentiation pattern of human epidermal keratinocytes. Molecular cancer 14, 1 (2015).
39 Liao, B. et al. Macrophage migration inhibitory factor contributes angiogenesis by up-regulating IL-8 and correlates with poor prognosis of patients with primary nasopharyngeal carcinoma. Journal of surgical oncology 102, 844-851 (2010).
40 Dumitru, C. A. et al. Tumor-derived macrophage migration inhibitory factor modulates the biology of head and neck cancer cells via neutrophil activation. International journal of cancer 129, 859-869 (2011).
41 Warner, K. A. et al. Endothelial cells enhance tumor cell invasion through a crosstalk mediated by CXC chemokine signaling. Neoplasia (New York, N.Y.) 10, 131-139 (2008).
42 Luan, J. et al. Mechanism and biological significance of constitutive expression of MGSA/GRO chemokines in malignant melanoma tumor progression. Journal of leukocyte biology 62, 588-597 (1997).
論文全文使用權限
  • 同意授權校內瀏覽/列印電子全文服務,於2025-01-25起公開。
  • 同意授權校外瀏覽/列印電子全文服務,於2025-01-25起公開。


  • 如您有疑問,請聯絡圖書館
    聯絡電話:(06)2757575#65773
    聯絡E-mail:etds@email.ncku.edu.tw